ARTICLE | Financial News
RNAi company Dicerna raises $100M follow-on
September 13, 2018 10:44 PM UTC
Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) raised $100 million on Sept. 6 via the sale of 7.7 million shares at $13.02 in a follow-on underwritten by Citigroup, Leerink, Stifel, H.C. Wainwright and SunTrust Robinson Humphrey. The price is an 18% discount to the company's close of $15.90 on Sept. 5, before the company proposed after hours to sell 6.2 million shares.
The company’s lead programs are designed to silence disease-driving genes in the liver and are based on GalXC technology, which allows attachment of N-acetylgalactosamine sugars to the extended region of RNAi molecules...
BCIQ Company Profiles